COMP <GO>
CRMD vs ABBV // DIVIDEND YIELD & FCF PAYOUT SAFETY
CorMedix Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CRMD 8
— ABBV 4
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ABBV
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
dividend-safety
0.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
dividend-safety
2.27%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 70.20% | +18.30 | CRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | 29.00% | +16.50 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 33.3x | -30.30 | CRMD | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | 24.60% | +23.60 | CRMD | /operating-margins <GO> |
| Net Profit Margin | 52.30% | 6.90% | +45.40 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | 5.33 | -3.52 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.3 | 65.1 | -39.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 113.1x | -109.60 | CRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $513.86B | -$513.26B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | ABBV REV | CRMD GROSS % | ABBV GROSS % | CRMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $61.16B | 88.5% | 70.2% | $172.8M | $17.82B |
| FY 2024 | $43.5M | $56.33B | 92.7% | 70.0% | -$50.7M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$38.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
ABBV // BETA 1.15